Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis
Objective. This study was aimed at exploring the prognostic and clinicopathological roles of aspartate aminotransferase-to-lymphocyte ratio index (ALRI) in patients with hepatocellular carcinoma via a meta-analysis. Methods. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowle...
Gespeichert in:
| Veröffentlicht in: | Disease markers 2022, Vol.2022, p.3533714-9 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | |
| container_start_page | 3533714 |
| container_title | Disease markers |
| container_volume | 2022 |
| creator | Peng, Xiulan Huang, Yali Zhang, Min Chen, Yan Zhang, Lihua He, Anbing Luo, Renfeng |
| description | Objective. This study was aimed at exploring the prognostic and clinicopathological roles of aspartate aminotransferase-to-lymphocyte ratio index (ALRI) in patients with hepatocellular carcinoma via a meta-analysis. Methods. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were comprehensively searched from inception to November 20, 2021. Pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) were used to evaluate the relationship between ALRI and overall survival (OS) as well as progression-free survival (PFS) in patients with hepatocellular carcinoma. Odds ratio (OR) and the corresponding 95% CI were also used to investigate correlations between clinical factors and ALRI in patients with hepatocellular carcinoma. Results. A total of 3914 patients with hepatocellular carcinoma from eleven retrospective cohorts were included in this meta-analysis. The combined results revealed that patients with hepatocellular carcinoma with elevated ALRI tended to have unfavorable OS (HR 1.53 [95% CI 1.25–1.82]; P |
| doi_str_mv | 10.1155/2022/3533714 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8850034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2631619584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-302055ca30021f030660e26d3b6e4a408a72cd3418295cac4a875c2a186761af3</originalsourceid><addsrcrecordid>eNp9kUtvEzEURkcIRNPCjjWyxAYJhl4_x2GBNIp4VAoC8VhbrseTuJrYqe1Jmz_Bb8ZDQgUsWPlK9-jofv6q6gmGVxhzfk6AkHPKKW0wu1fNsGx4LQWF-9UMSCNrIAxOqtOUrgAwmbP5w-qEciwFFnxW_fgcw8qHlJ1B2ndoMTjvjB7QV7fyri-jNxaFHrVpq2PW2aJ243zIUfvU26iTrXOol_vNdh3Mvqy_6OwCuvCdvUXOT4PbuW7UQ0I3Lq_R0u1sRIvJG1-jFn20Wdet18M-ufSoetAX0j4-vmfV93dvvy0-1MtP7y8W7bI2jMlcUyDAudEUgOAeKAgBloiOXgrLNAOpG2I6yrAk84IZpsuvGKJL6kZg3dOz6s3Bux0vN7Yz1pdAg9pGt9Fxr4J26u-Nd2u1CjslJQegrAieHwUxXI82ZbVxydhh0N6GMSkiKBZ4zuWEPvsHvQpjLIF_USAkLgcX6uWBMjGkFG1_dwwGNRWtpqLVseiCP_0zwB38u9kCvDgAa-c7feP-r_sJq0-xCA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630681408</pqid></control><display><type>article</type><title>Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis</title><source>MEDLINE</source><source>Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Peng, Xiulan ; Huang, Yali ; Zhang, Min ; Chen, Yan ; Zhang, Lihua ; He, Anbing ; Luo, Renfeng</creator><contributor>Kim, Young-Kug</contributor><creatorcontrib>Peng, Xiulan ; Huang, Yali ; Zhang, Min ; Chen, Yan ; Zhang, Lihua ; He, Anbing ; Luo, Renfeng ; Kim, Young-Kug</creatorcontrib><description>Objective. This study was aimed at exploring the prognostic and clinicopathological roles of aspartate aminotransferase-to-lymphocyte ratio index (ALRI) in patients with hepatocellular carcinoma via a meta-analysis. Methods. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were comprehensively searched from inception to November 20, 2021. Pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) were used to evaluate the relationship between ALRI and overall survival (OS) as well as progression-free survival (PFS) in patients with hepatocellular carcinoma. Odds ratio (OR) and the corresponding 95% CI were also used to investigate correlations between clinical factors and ALRI in patients with hepatocellular carcinoma. Results. A total of 3914 patients with hepatocellular carcinoma from eleven retrospective cohorts were included in this meta-analysis. The combined results revealed that patients with hepatocellular carcinoma with elevated ALRI tended to have unfavorable OS (HR 1.53 [95% CI 1.25–1.82]; P<0.001). Pooled HRs revealed that high ALRI was an independent risk factor for inferior PFS in patients with hepatocellular carcinoma (HR 1.36 [95% CI 1.10–1.63]; P<0.001). In addition, high ALRI was strongly associated with male sex (OR 1.32 [95% CI 1.02–1.70]; P=0.035), presence of cirrhosis (OR 1.68 [95% CI 1.01–2.81]; P=0.046), larger tumor size (OR 2.25 [95% CI 1.31–3.88]; P<0.001), presence of portal vein tumor thrombus (OR 2.50 [95% CI 1.52–4.11]; P<0.001), and distant metastasis (OR 1.72 [95% CI 1.05-2.82]; P=0.031). Conclusion. Elevated ALRI in patients with hepatocellular carcinoma predicted inferior survival outcomes and was strongly associated with some important features of hepatocellular carcinoma.</description><identifier>ISSN: 0278-0240</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2022/3533714</identifier><identifier>PMID: 35186165</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Aspartate aminotransferase ; Aspartate Aminotransferases - blood ; Biomarkers ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Cirrhosis ; Clinical significance ; Confidence intervals ; Hepatitis ; Hepatocellular carcinoma ; Humans ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Liver Neoplasms - blood ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Lymphocyte Count ; Lymphocytes ; Medical prognosis ; Meta-analysis ; Metastases ; Patients ; Portal vein ; Prognosis ; Retrospective Studies ; Review ; Risk analysis ; Risk factors ; Survival ; Survival analysis ; Survival Rate ; Thrombosis ; Transaminases ; Tumors</subject><ispartof>Disease markers, 2022, Vol.2022, p.3533714-9</ispartof><rights>Copyright © 2022 Xiulan Peng et al.</rights><rights>Copyright © 2022 Xiulan Peng et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Xiulan Peng et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-302055ca30021f030660e26d3b6e4a408a72cd3418295cac4a875c2a186761af3</citedby><cites>FETCH-LOGICAL-c448t-302055ca30021f030660e26d3b6e4a408a72cd3418295cac4a875c2a186761af3</cites><orcidid>0000-0003-2795-3955 ; 0000-0002-0678-231X ; 0000-0001-8336-4253 ; 0000-0002-1778-4732 ; 0000-0001-9747-551X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850034/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850034/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35186165$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kim, Young-Kug</contributor><creatorcontrib>Peng, Xiulan</creatorcontrib><creatorcontrib>Huang, Yali</creatorcontrib><creatorcontrib>Zhang, Min</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Zhang, Lihua</creatorcontrib><creatorcontrib>He, Anbing</creatorcontrib><creatorcontrib>Luo, Renfeng</creatorcontrib><title>Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>Objective. This study was aimed at exploring the prognostic and clinicopathological roles of aspartate aminotransferase-to-lymphocyte ratio index (ALRI) in patients with hepatocellular carcinoma via a meta-analysis. Methods. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were comprehensively searched from inception to November 20, 2021. Pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) were used to evaluate the relationship between ALRI and overall survival (OS) as well as progression-free survival (PFS) in patients with hepatocellular carcinoma. Odds ratio (OR) and the corresponding 95% CI were also used to investigate correlations between clinical factors and ALRI in patients with hepatocellular carcinoma. Results. A total of 3914 patients with hepatocellular carcinoma from eleven retrospective cohorts were included in this meta-analysis. The combined results revealed that patients with hepatocellular carcinoma with elevated ALRI tended to have unfavorable OS (HR 1.53 [95% CI 1.25–1.82]; P<0.001). Pooled HRs revealed that high ALRI was an independent risk factor for inferior PFS in patients with hepatocellular carcinoma (HR 1.36 [95% CI 1.10–1.63]; P<0.001). In addition, high ALRI was strongly associated with male sex (OR 1.32 [95% CI 1.02–1.70]; P=0.035), presence of cirrhosis (OR 1.68 [95% CI 1.01–2.81]; P=0.046), larger tumor size (OR 2.25 [95% CI 1.31–3.88]; P<0.001), presence of portal vein tumor thrombus (OR 2.50 [95% CI 1.52–4.11]; P<0.001), and distant metastasis (OR 1.72 [95% CI 1.05-2.82]; P=0.031). Conclusion. Elevated ALRI in patients with hepatocellular carcinoma predicted inferior survival outcomes and was strongly associated with some important features of hepatocellular carcinoma.</description><subject>Aspartate aminotransferase</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Biomarkers</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cirrhosis</subject><subject>Clinical significance</subject><subject>Confidence intervals</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Lymphocyte Count</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>Metastases</subject><subject>Patients</subject><subject>Portal vein</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Review</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Survival Rate</subject><subject>Thrombosis</subject><subject>Transaminases</subject><subject>Tumors</subject><issn>0278-0240</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUtvEzEURkcIRNPCjjWyxAYJhl4_x2GBNIp4VAoC8VhbrseTuJrYqe1Jmz_Bb8ZDQgUsWPlK9-jofv6q6gmGVxhzfk6AkHPKKW0wu1fNsGx4LQWF-9UMSCNrIAxOqtOUrgAwmbP5w-qEciwFFnxW_fgcw8qHlJ1B2ndoMTjvjB7QV7fyri-jNxaFHrVpq2PW2aJ243zIUfvU26iTrXOol_vNdh3Mvqy_6OwCuvCdvUXOT4PbuW7UQ0I3Lq_R0u1sRIvJG1-jFn20Wdet18M-ufSoetAX0j4-vmfV93dvvy0-1MtP7y8W7bI2jMlcUyDAudEUgOAeKAgBloiOXgrLNAOpG2I6yrAk84IZpsuvGKJL6kZg3dOz6s3Bux0vN7Yz1pdAg9pGt9Fxr4J26u-Nd2u1CjslJQegrAieHwUxXI82ZbVxydhh0N6GMSkiKBZ4zuWEPvsHvQpjLIF_USAkLgcX6uWBMjGkFG1_dwwGNRWtpqLVseiCP_0zwB38u9kCvDgAa-c7feP-r_sJq0-xCA</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Peng, Xiulan</creator><creator>Huang, Yali</creator><creator>Zhang, Min</creator><creator>Chen, Yan</creator><creator>Zhang, Lihua</creator><creator>He, Anbing</creator><creator>Luo, Renfeng</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2795-3955</orcidid><orcidid>https://orcid.org/0000-0002-0678-231X</orcidid><orcidid>https://orcid.org/0000-0001-8336-4253</orcidid><orcidid>https://orcid.org/0000-0002-1778-4732</orcidid><orcidid>https://orcid.org/0000-0001-9747-551X</orcidid></search><sort><creationdate>2022</creationdate><title>Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis</title><author>Peng, Xiulan ; Huang, Yali ; Zhang, Min ; Chen, Yan ; Zhang, Lihua ; He, Anbing ; Luo, Renfeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-302055ca30021f030660e26d3b6e4a408a72cd3418295cac4a875c2a186761af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aspartate aminotransferase</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Biomarkers</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cirrhosis</topic><topic>Clinical significance</topic><topic>Confidence intervals</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Lymphocyte Count</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>Metastases</topic><topic>Patients</topic><topic>Portal vein</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Review</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Survival Rate</topic><topic>Thrombosis</topic><topic>Transaminases</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Xiulan</creatorcontrib><creatorcontrib>Huang, Yali</creatorcontrib><creatorcontrib>Zhang, Min</creatorcontrib><creatorcontrib>Chen, Yan</creatorcontrib><creatorcontrib>Zhang, Lihua</creatorcontrib><creatorcontrib>He, Anbing</creatorcontrib><creatorcontrib>Luo, Renfeng</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Xiulan</au><au>Huang, Yali</au><au>Zhang, Min</au><au>Chen, Yan</au><au>Zhang, Lihua</au><au>He, Anbing</au><au>Luo, Renfeng</au><au>Kim, Young-Kug</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2022</date><risdate>2022</risdate><volume>2022</volume><spage>3533714</spage><epage>9</epage><pages>3533714-9</pages><issn>0278-0240</issn><eissn>1875-8630</eissn><abstract>Objective. This study was aimed at exploring the prognostic and clinicopathological roles of aspartate aminotransferase-to-lymphocyte ratio index (ALRI) in patients with hepatocellular carcinoma via a meta-analysis. Methods. The PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were comprehensively searched from inception to November 20, 2021. Pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) were used to evaluate the relationship between ALRI and overall survival (OS) as well as progression-free survival (PFS) in patients with hepatocellular carcinoma. Odds ratio (OR) and the corresponding 95% CI were also used to investigate correlations between clinical factors and ALRI in patients with hepatocellular carcinoma. Results. A total of 3914 patients with hepatocellular carcinoma from eleven retrospective cohorts were included in this meta-analysis. The combined results revealed that patients with hepatocellular carcinoma with elevated ALRI tended to have unfavorable OS (HR 1.53 [95% CI 1.25–1.82]; P<0.001). Pooled HRs revealed that high ALRI was an independent risk factor for inferior PFS in patients with hepatocellular carcinoma (HR 1.36 [95% CI 1.10–1.63]; P<0.001). In addition, high ALRI was strongly associated with male sex (OR 1.32 [95% CI 1.02–1.70]; P=0.035), presence of cirrhosis (OR 1.68 [95% CI 1.01–2.81]; P=0.046), larger tumor size (OR 2.25 [95% CI 1.31–3.88]; P<0.001), presence of portal vein tumor thrombus (OR 2.50 [95% CI 1.52–4.11]; P<0.001), and distant metastasis (OR 1.72 [95% CI 1.05-2.82]; P=0.031). Conclusion. Elevated ALRI in patients with hepatocellular carcinoma predicted inferior survival outcomes and was strongly associated with some important features of hepatocellular carcinoma.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>35186165</pmid><doi>10.1155/2022/3533714</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2795-3955</orcidid><orcidid>https://orcid.org/0000-0002-0678-231X</orcidid><orcidid>https://orcid.org/0000-0001-8336-4253</orcidid><orcidid>https://orcid.org/0000-0002-1778-4732</orcidid><orcidid>https://orcid.org/0000-0001-9747-551X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0240 |
| ispartof | Disease markers, 2022, Vol.2022, p.3533714-9 |
| issn | 0278-0240 1875-8630 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8850034 |
| source | MEDLINE; Wiley Online Library; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Aspartate aminotransferase Aspartate Aminotransferases - blood Biomarkers Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Cirrhosis Clinical significance Confidence intervals Hepatitis Hepatocellular carcinoma Humans Liver cancer Liver cirrhosis Liver diseases Liver Neoplasms - blood Liver Neoplasms - mortality Liver Neoplasms - pathology Lymphocyte Count Lymphocytes Medical prognosis Meta-analysis Metastases Patients Portal vein Prognosis Retrospective Studies Review Risk analysis Risk factors Survival Survival analysis Survival Rate Thrombosis Transaminases Tumors |
| title | Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A40%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20and%20Clinical%20Significance%20of%20Aspartate%20Aminotransferase-to-Lymphocyte%20Ratio%20Index%20in%20Individuals%20with%20Liver%20Cancer:%20A%20Meta-Analysis&rft.jtitle=Disease%20markers&rft.au=Peng,%20Xiulan&rft.date=2022&rft.volume=2022&rft.spage=3533714&rft.epage=9&rft.pages=3533714-9&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2022/3533714&rft_dat=%3Cproquest_pubme%3E2631619584%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630681408&rft_id=info:pmid/35186165&rfr_iscdi=true |